Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03602547 | Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. | unknown | Phase 2 | 40 | AnewPharmaINDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03986515 | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03966456 |
| Real World Study of Four PD-1 Agents in China |
| unknown |
| — |
| 500 |
| The Affiliated Hospital of Qingdao UniversityOTHER |
| 1 |
| May 29, 2019 |
| clinicaltrials |
| NCT02909517 | The Role of Inflammation in Ocular Tumours | unknown | — | 30 | Unity Health TorontoOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT03955354 | PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT02352428 | Skin Cancer Screening Education Study(SCSES) | unknown | N/A | 113 | Association of Dermatological Prevention, GermanyOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03917069 | Nab-PCE vs PC for MM After Failure of Anti-PD-1 | unknown | Phase 2 | 145 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02861209 | Collaborative Network to Take Responsibility for Oral Anticancer Therapy(CONTACT) | unknown | N/A | 228 | KU LeuvenOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03190824 | Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma | unknown | Phase 2 | 4 | Syneos HealthOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03903458 | Tinostamustine and Nivolumab in Advanced Melanoma(ENIgMA) | unknown | Phase 1 | 21 | Markus JoergerOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03353402 | Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy | unknown | Phase 1 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 3, 2019 | clinicaltrials |
| NCT00849407 | Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma(M3) | unknown | — | 2,000 | Medical University of ViennaOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01920516 | Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment(ILI) | unknown | — | 40 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03454282 | Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial(DIgesT) | unknown | N/A | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03818893 | Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII | unknown | Phase 2 | 46 | Osaka UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT03822988 | ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS(PADAONCODERM) | unknown | — | 150 | Central Hospital, Nancy, FranceOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT03797053 | Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology(EXPEVIVO-CTC) | unknown | — | 450 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00604136 | Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy | unknown | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03362138 | Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions(NNCD) | unknown | — | 80 | Assuta Hospital SystemsOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT03621462 | Elucid Labs AIDA™ - Labelled Image Acquisition Protocol | unknown | N/A | 4,000 | Elucid Labs Inc.INDUSTRY | 1 | Aug 8, 2018 | clinicaltrials |
| NCT01167998 | Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions | unknown | — | 20 | Hadassah Medical OrganizationOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03454919 | Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations | unknown | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 0 | Mar 6, 2018 | clinicaltrials |
| NCT03449615 | Validation of Ferromagnetic Tracer in Melanoma Sentinel Node(IMINEM) | unknown | — | 186 | Sociedad Española de Oncología QuirúrgicaOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT03435302 | HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma | unknown | Phase 3 | 204 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT03422445 | A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03138642 | Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT03383237 | Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 27, 2017 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT03048253 | A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c | unknown | — | 30 | OrienGene Biotechnology Ltd.INDUSTRY | 1 | Oct 2, 2017 | clinicaltrials |
| NCT02625337 | Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients(IMPemBra) | unknown | Phase 2 | 32 | The Netherlands Cancer InstituteOTHER | 1 | Sep 15, 2017 | clinicaltrials |
| NCT02023710 | Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma | unknown | Phase 2 | 182 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT02452294 | Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)(BUMPER) | unknown | Phase 2 | 22 | University Hospital TuebingenOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT03132090 | Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI | unknown | N/A | 106 | University Hospital TuebingenOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT03095079 | Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma | unknown | Phase 2 | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT02379000 | TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy | unknown | Phase 4 | 50 | Charite University, Berlin, GermanyOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02142244 | Fluorescence Surgery for Sentinel Node Identification in Melanoma | unknown | N/A | 318 | Barretos Cancer HospitalOTHER | 1 | Feb 2, 2017 | clinicaltrials |
| NCT03033485 | 18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis | unknown | N/A | 50 | Xijing HospitalOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT02990416 | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 63 | Virogen Biotechnology Inc.INDUSTRY | 1 | Dec 13, 2016 | clinicaltrials |
| NCT02962947 | MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients | unknown | Phase 2 / Phase 3 | 546 | Azienda Sanitaria di FirenzeOTHER | 0 | Nov 15, 2016 | clinicaltrials |
| NCT02938728 | Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma(PREDIMEL) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 25, 2016 | clinicaltrials |
| NCT02335476 | Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography | unknown | — | 100 | National Taiwan University HospitalOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01878396 | Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors(CMCBRAF) | unknown | — | 200 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT02581228 | Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy | unknown | — | 500 | Optimata Ltd.INDUSTRY | 1 | Sep 27, 2016 | clinicaltrials |
| NCT02884362 | Prospective Melanoma Database | unknown | — | 10,000 | Institut Claudius RegaudOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02838433 | Study of Anti-telomerase T CD4 Immunity in Melanoma(LyTéloMel) | unknown | N/A | 200 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 20, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 5, 2019source: clinicaltrials